Scott Requadt - 03 Jul 2023 Form 4 Insider Report for Talaris Therapeutics, Inc. (TRML)

Signature
/s/ Mary Kay Fenton, attorney-in-fact
Issuer symbol
TRML
Transactions as of
03 Jul 2023
Net transactions value
-$36,301
Form type
4
Filing time
06 Jul 2023, 17:19:16 UTC
Previous filing
03 Feb 2023
Next filing
16 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TALS Common Stock Tax liability $36,301 -11,786 -2% $3.08 578,403 03 Jul 2023 Direct F1
holding TALS Common Stock 449,766 03 Jul 2023 See footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units ("RSUs") were granted to the Reporting Person by the issuer under the Issuer's 2021 Stock Option and Incentive Plan on September 10, 2022. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. This transaction reflects the sufficient shares sold to pay applicable income taxes related to the 50% vesting on July 1, 2023.
F2 These shares are held by Requadt Family Limited Partnership. The reporting person has voting and dispositive power over the shares beneficially owned by Requadt Family Limited Partnership.